Cerebrolysin
Also called FPF-1070
Intravenous (into a vein)Human study reference
Research reference
Human study
CARS stroke-rehabilitation trial
30 mL daily for 21 days, starting 24–72 hours after stroke
21-day course plus rehabilitation; primary motor assessment at day 90
Muresanu et al., Stroke (2016) ↗When results may show
- When change was measured
- Arm-function recovery was measured at day 90. The exploratory result was not a study of healthy-person cognition.
- When to assess
- 21-day course plus rehabilitation; primary motor assessment at day 90
- Conditions and limitations
- Adults in early rehabilitation after stroke. This is a clinical IV mixture measured in mL, not a defined single peptide dose. It cannot become a pen, under-the-skin or nootropic starter.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Sources: Muresanu et al., Stroke (2016)
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Where these numbers come from
- Muresanu et al., Stroke (2016)This is a clinical IV mixture measured in mL, not a defined single peptide dose. It cannot become a pen, under-the-skin or nootropic starter.